×

Fast parameters estimation in medication efficacy assessment model for heart failure treatment. (English) Zbl 1401.92111

Summary: Introduction. Heart failure (HF) is a common and potentially fatal condition. Cardiovascular research has focused on medical therapy for HF. Theoretical modelling could enable simulation and evaluation of the effectiveness of medications. Furthermore, the models could also help predict patients’ cardiac response to the treatment which will be valuable for clinical decision-making. Methods. This study presents a fast parameters estimation algorithm for constructing a cardiovascular model for medicine evaluation. The outcome of HF treatment is assessed by hemodynamic parameters and a comprehensive index furnished by the model. Angiotensin-converting enzyme inhibitors (ACEIs) were used as a model drug in this study. Results. Our simulation results showed different treatment responses to enalapril and lisinopril, which are both ACEI drugs. A dose-effect was also observed in the model simulation. Conclusions. Our results agreed well with the findings from clinical trials and previous literature, suggesting the validity of the model.

MSC:

92C50 Medical applications (general)
PDFBibTeX XMLCite
Full Text: DOI

References:

[1] S. A. Hunt, D. W. Baker, M. H. Chin et al., “ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult,” Circulation, vol. 112, no. 12, pp. 154-235, 2005.
[2] W. J. Remme and K. Swedberg, “Guidelines for the diagnosis and treatment of chronic heart failure,” European Heart Journal, vol. 22, no. 17, pp. 1527-1560, 2001. · doi:10.1053/euhj.2001.2783
[3] B. M. Massie and N. B. Shah, “Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management,” American Heart Journal, vol. 133, no. 6, pp. 703-712, 1997. · doi:10.1016/S0002-8703(97)70173-X
[4] W. J. Remme, J. G. F. Cleland, H. Dargie et al., “The treatment of heart failure,” European Heart Journal, vol. 18, no. 5, pp. 736-753, 1997.
[5] A. W. Haider, M. G. Larson, S. S. Franklin, and D. Levy, “Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study,” Annals of Internal Medicine, vol. 138, no. 1, pp. 10-16, 2003.
[6] M. Gheorghiade, W. T. Abraham, N. M. Albert et al., “Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure,” Journal of the American Medical Association, vol. 296, no. 18, pp. 2217-2226, 2006. · doi:10.1001/jama.296.18.2217
[7] M. Diaz-Insua and M. Delgado, “Modeling and simulation of the human cardiovascular system with bond graph: a basic development,” Computers in Cardiology, vol. 11, no. 8, pp. 393-396, 1996.
[8] M. Ursino and E. Magosso, “Role of short-term cardiovascular regulation in heart period variability: a modeling study,” American Journal of Physiology, vol. 284, no. 4, pp. H1479-H1493, 2003.
[9] R. Zelis, D. T. Mason, and E. Braunwald, “A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure,” Journal of Clinical Investigation, vol. 47, no. 4, pp. 960-970, 1968.
[10] G. F. Mitchell, J. C. Tardif, J. M. O. Arnold et al., “Pulsatile hemodynamics in congestive heart failure,” Hypertension, vol. 38, no. 6, pp. 1433-1439, 2001.
[11] H. Tsuruta, T. Sato, and N. Ikeda, “Mathematical model of cardiovascular mechanics for diagnostic analysis and treatment of heart failure-part 2: analysis of vasodilator therapy and planning of optimal drug therapy,” Medical and Biological Engineering and Computing, vol. 32, no. 1, pp. 12-18, 1994.
[12] Y. Gong, Q. Hu, G. Ning, S. Gong, and J. Yan, “Simulate heart failure by a mathematical model,” in Proceedings of the 3rd International Conference on Bioinformatics and Biomedical Engineering (iCBBE ’09), vol. 11, pp. 2447-2450, June 2009. · doi:10.1109/ICBBE.2009.5163387
[13] Z. Luo, S. Zhang, Y. Yang, et al., Engineering Analysis for Pulse Wave and Its Application in Clinical Practice, Science Press, Beijing, China, 2006.
[14] M. Peltier, D. Houpe, A. Cohen-Solal, M. Béguin, F. Levy, and C. Tribouilloy, “Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study,” International Journal of Cardiology, vol. 118, no. 3, pp. 363-369, 2007. · doi:10.1016/j.ijcard.2006.07.033
[15] J. N. Nanas, G. Alexopoulos, M. I. Anastasiou-Nana et al., “Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study,” Journal of the American College of Cardiology, vol. 36, no. 7, pp. 2090-2095, 2000. · doi:10.1016/S0735-1097(00)01025-1
[16] L. M. Louis, J. Dirk, G. Michael, Z. Zilahi, W. R. Meyer, and R. Willenheimer, “The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure,” International Journal of Cardiology, vol. 40, no. 4, pp. 1-5, 2009.
[17] J. Bai and S. Wen, “Efficacy of irbesartan versus enalapril in treatment of mild and moderate hypertension,” Modern Medicine & Health, vol. 25, no. 16, pp. 2421-2422, 2009.
[18] R. C. Hermida, D. E. Ayala, Y. Khder, and C. Calvo, “Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial,” Clinical Therapeutics, vol. 30, no. 1, pp. 108-120, 2008. · doi:10.1016/j.clinthera.2008.01.012
[19] H. J. Gomez, V. J. Cirillo, J. A. Sromovsky et al., “Lisinopril dose-response relationship in essential hypertension,” British Journal of Clinical Pharmacology, vol. 28, no. 4, pp. 415-420, 1989.
[20] R. Botero, H. Matiz, E. María et al., “Efficacy and safety of valsartan compared with enalapril at different altitudes,” International Journal of Cardiology, vol. 72, no. 3, pp. 247-254, 2000. · doi:10.1016/S0167-5273(99)00194-1
[21] Y. Kaminsky, A. Suslikov, and E. Kosenko, “Specific and pronounced impacts of lisinopril and lisinopril plus simvastatin on erythrocyte antioxidant enzymes,” Journal of Clinical Pharmacology, vol. 50, no. 2, pp. 180-187, 2010. · doi:10.1177/0091270009344854
[22] M. D. McMurray and J. V. John, “Systolic heart failure reply,” New England Journal of Medicine, vol. 362, no. 16, pp. 1545-1546, 2010.
[23] K. Simpson and B. Jarvis, “Lisinopril: a review of its use in congestive heart failure,” Drugs, vol. 59, no. 5, pp. 1149-1167, 2000.
[24] J. Menne, C. Farsang, L. Deák et al., “Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial,” Journal of Hypertension, vol. 26, no. 9, pp. 1860-1867, 2008. · doi:10.1097/HJH.0b013e32830508aa
[25] W. F. Terpstra, J. F. May, A. J. Smit, P. A. De Graeff, B. Meyboom-De Jong, and H. J. G. M. Crijns, “Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial),” Journal of Hypertension, vol. 22, no. 7, pp. 1309-1316, 2004. · doi:10.1097/01.hjh.0000125412.50839.b5
[26] I. Enström, T. Thulin, and L. H. Lindholm, “Comparison between enalapril and lisinopril in mild-moderate hypertension: a comprehensive model for evaluation of drug efficacy,” Blood Pressure, vol. 1, no. 2, pp. 102-107, 1992.
[27] S. Mazimba, T. Patel, and N. Grant, “Medical advances in the evaluation and treatment of heart failure,” Emergency Medicine Reports, vol. 31, no. 19, pp. 217-226, 2010.
[28] K. Dickstein, T. Aarsland, and K. Tjelta, “A comparison of hypotensive responses after oral and intravenous administration of enalapril and lisinopril in chronic heart failure,” Journal of Cardiovascular Pharmacology, vol. 9, no. 6, pp. 705-710, 1987.
[29] A. Sandoval, P. Larrabee, D. G. Renlund, J. B. O’Connell, and M. R. Bristow, “Lisinopril lowers cardiac adrenergic drive and increases \beta -receptor density in the failing human heart,” Circulation, vol. 88, no. 2, pp. 472-480, 1993.
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.